Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BYNPJ vaccines

Limited tissue persistence confirms attenuation of live-attenuated chikungunya vaccine VLA1553 in non-human primates.

  • Pierre Roques1,2
  • Andrea Fritzer3
  • Nathalie Dereuddre-Bosquet1
  • Laetitia Bossevot1
  • Quentin Pascal1
  • Roger Le Grand1
  • Urban Lundberg4
  • Andreas Meinke4
4 affiliations
  1. 1Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, INSERM, CEA, Fontenay-aux-Roses, France.
  2. 2Institut Pasteur de Guinée, Conakry, Guinea.
  3. 3Valneva Austria GmbH, Vienna, Austria. [email protected].
  4. 4Valneva Austria GmbH, Vienna, Austria.
Read full textPDFDOICite

Abstract

Chronic chikungunya disease is caused by the mosquito-borne chikungunya virus (CHIKV) induced by viral persistence in target tissues. To investigate the risk of viral persistence of the approved live-attenuated vaccine IXCHIQ® (VLA1553), cynomolgus macaques received a 100-fold higher dose than the approved dose for IXCHIQ® or wild-type CHIKV. In VLA1553-treated NHPs, fever was transient, coinciding with peak viremia, with no significant virus detected in tissues except for immune organs. WT CHIKV-treated NHPs developed fever persisting for several days with higher peak viremias, and virus was consistently detected in tissues at higher levels than in VLA1553-treated animals. Additionally, WT CHIKV-treated NHPs showed more CHIKV in saliva and vaginal fluid, lymphocytopenia, increased liver enzymes and plasma prostaglandin E₂, and higher expression of pro-inflammatory cytokines and chemokines associated with WT CHIKV disease than VLA1553-treated animals. This study demonstrated attenuation of vaccine strain VLA1553, with no critical observations in non-human primates (NHPs) following administration of a high dose.

Related

  1. Detection of persistent viremia by a live attenuated vaccine strain of the chikungunya virus in a blood donor
    Pierre Gallian, Laura Pezzi, Khalil Helzy +10
    International Journal of Infectious DiseasesPeer-reviewedCC BY-NC-NDFull text1 citedEpidemiology & public healthHAL
  2. Long IVUS-attenuated plaque without no-reflow: histological findings of captured embolic debris and implications for the interpretation of IVUS attenuation: a case report
    Kenta Suzuki, Tomomi Koizumi, Yukinori Inadome
    European Heart Journal. Case ReportsPeer-reviewedCC BY-NC 4.0Full textCardiovascular medicinePMC
  3. Experimental aspects of bone marrow transplantation in primates
    D.W. van Bekkum, H. Balner, K.A. Dicke +1
    PubMedPeer-reviewedLicence not stated21 citedGeneral medicineOpenAlex
  4. Translational Pharmacokinetics and Pharmacodynamics of a Cationic mRNA-Lipid Nanoparticle from Mice to Non-Human Primates
    C. M. Dunne, K. Radloff, L. Gkionis +8
    bioRxivPreprintAll rights reservedFull textPharmacology & toxicologybioRxiv
  5. Non-identifiability of autochthonous chikungunya risk from surveillance data, Japan, 2011–2025
    Satoshi Kutsuna
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthCrossref

Cite

BibTeXRIS
BibTeX
@article{roques2026limited,
  title = {{Limited tissue persistence confirms attenuation of live-attenuated chikungunya vaccine VLA1553 in non-human primates.}},
  author = {Pierre Roques and Andrea Fritzer and Nathalie Dereuddre-Bosquet and Laetitia Bossevot and Quentin Pascal and Roger Le Grand and Urban Lundberg and Andreas Meinke},
  journal = {NPJ vaccines},
  year = {2026},
  month = jul,
  doi = {10.1038/s41541-026-01535-4},
  url = {https://europepmc.org/article/MED/42907477},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Limited tissue persistence confirms attenuation of live-attenuated chikungunya vaccine VLA1553 in non-human primates.
AU  - Pierre Roques
AU  - Andrea Fritzer
AU  - Nathalie Dereuddre-Bosquet
AU  - Laetitia Bossevot
AU  - Quentin Pascal
AU  - Roger Le Grand
AU  - Urban Lundberg
AU  - Andreas Meinke
PY  - 2026
DA  - 2026/07/01
JO  - NPJ vaccines
DO  - 10.1038/s41541-026-01535-4
UR  - https://europepmc.org/article/MED/42907477
AB  - Chronic chikungunya disease is caused by the mosquito-borne chikungunya virus (CHIKV) induced by viral persistence in target tissues. To investigate the risk of viral persistence of the approved live-attenuated vaccine IXCHIQ® (VLA1553), cynomolgus macaques received a 100-fold higher dose than the approved dose for IXCHIQ® or wild-type CHIKV. In VLA1553-treated NHPs, fever was transient, coinciding with peak viremia, with no significant virus detected in tissues except for immune organs. WT CHIKV-treated NHPs developed fever persisting for several days with higher peak viremias, and virus was consistently detected in tissues at higher levels than in VLA1553-treated animals. Additionally, WT CHIKV-treated NHPs showed more CHIKV in saliva and vaginal fluid, lymphocytopenia, increased liver enzymes and plasma prostaglandin E₂, and higher expression of pro-inflammatory cytokines and chemokines associated with WT CHIKV disease than VLA1553-treated animals. This study demonstrated attenuation of vaccine strain VLA1553, with no critical observations in non-human primates (NHPs) following administration of a high dose.
SN  - 2059-0105
ER  -